Why the study?
Evidence for pharmacologic therapy in symptomatic HFpEF is very limited, making optimal treatment selection for diabetic HFpEF challenging despite high prevalence and poor outcomes.
What is the current evidence for pharmacological therapy in patients with diabetic HFpEF?
What is the current evidence for pharmacological therapy in patients with diabetic HFpEF?
This narrative review highlights the limited evidence and challenges in selecting optimal pharmacological therapy for patients with diabetic HFpEF.
Diabetes is associated with several diabetic-related abnormalities which increase the risk of onset or worsening of heart failure. Recent studies showed that the majority of diabetic patients present with heart failure with preserved ejection fraction (HFpEF), and the prevalence of HFpEF in diabetics is alarming. Moreover, outcomes in HFpEF are poor and could be compared to those of heart failure with reduced ejection fraction (HFrEF), with 1-year mortality ranging between 10 and 30%. In contrast to HFrEF, there is very limited evidence for pharmacologic therapy in symptomatic patients with preserved ejection fraction, and therefore, the optimal selection of treatment for diabetic HFpEF remains challenging. This narrative review article summarizes the currently available data on the pharmacological treatment of HFpEF in patients with diabetes.
No takes yet. Share an insight, caveat, or question.
Benko et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: